Lung cancer immunotherapy: PD-L1 results and where ivonescimab fits

What the PD-L1 result tells you

PD-L1 testing examines protein expression in a tumor sample. In NSCLC, the report often uses a tumor proportion score, or TPS. This expresses the proportion of evaluated tumor cells with the relevant staining. Ask for the actual score and the test used, not only the word positive.

Different treatments and indications use different thresholds. A result can help estimate the usefulness of a particular treatment, but it does not tell the whole story about response. The pathology, disease burden and molecular findings remain part of the decision.

Sources and references: [1]

Check molecular results before choosing by PD-L1 alone

An EGFR mutation or ALK fusion can lead to a targeted-treatment pathway even when PD-L1 is high. This is why molecular testing and PD-L1 testing should be considered together. Starting from the score alone can miss the result most relevant to the first medicine.

If results are still pending, ask the oncologist how they might change the plan and whether your condition allows time to wait. When symptoms require urgent care, the team can explain how treatment and outstanding tests will proceed together.

Sources and references: [1] [2]

Why immunotherapy may be given alone or with chemotherapy

In advanced NSCLC without a suitable molecular target, a sufficiently high PD-L1 result may support single-agent checkpoint treatment in an appropriate patient. A combination with chemotherapy may be considered for other PD-L1 levels or clinical situations. The choice also depends on histology and fitness.

Ask what each component contributes and how long it is intended to continue. A plan that begins with several drugs may later move to maintenance treatment. Knowing that sequence helps you compare appointment burden, expected side effects and the time needed away from home.

Sources and references: [1]

Immunotherapy can also be part of earlier-stage care

Checkpoint medicines are used in selected resectable cancers before or after surgery and in some patients after definitive chemoradiation. These are separate treatment settings with different eligibility requirements. A recommendation from a stage IV article should not be carried over automatically to postoperative care.

Ask which evidence matches your stage and whether EGFR or ALK results change the recommendation. After chest radiation, the team also considers recovery and lung inflammation. The proposed treatment should be tied to your complete sequence of care.

Sources and references: [1]

Where ivonescimab enters the discussion in China

Ivonescimab targets PD-1 and VEGF. Its China uses include combination with pemetrexed and carboplatin for EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC after EGFR-TKI progression. In China, first-line ivonescimab monotherapy is approved for locally advanced or metastatic NSCLC with PD-L1 TPS of at least 1% and no EGFR mutation or ALK alteration. China also approved ivonescimab with chemotherapy for first-line advanced squamous NSCLC in August 2026.

Each setting calls for a different conversation. Bring the full molecular report and treatment history so the hospital can check the current local label and whether the proposed regimen fits.

Sources and references: [3] [4] [7]

Read a drug comparison in the right treatment setting

HARMONi-2 compared ivonescimab with pembrolizumab alone in previously untreated PD-L1-positive advanced NSCLC in China. It found improved progression-free survival with ivonescimab at the reported analysis. This comparison is most relevant when a patient and oncologist are weighing those first-line single-agent options. If chemotherapy is also being considered, ask how the evidence for the proposed combination fits your symptoms, tumor burden and molecular results.

When a drug is described as better, ask which patients were studied, what it was compared with and whether the outcome was tumor shrinkage, time without progression or survival. Your consultation should translate those findings into a choice that fits your cancer and health.

Sources and references: [5]

Know which symptoms need an early call

Checkpoint treatment can inflame the lungs, bowel, liver, thyroid and other organs. New breathlessness, persistent diarrhea, marked weakness or other unexplained changes should be reported promptly. Immune-related effects can develop during treatment or after it has stopped.

Tell the team about autoimmune disease, organ transplantation and medicines that suppress immunity. A regimen with VEGF targeting also needs assessment of concerns such as bleeding, blood pressure and wound healing. Get a treatment-specific contact plan, including what to do outside clinic hours.

Sources and references: [1] [6]

Prepare a useful immunotherapy review

If you are considering Shanghai, the most useful question is whether your cancer fits a specific treatment pathway. EastMedGo can help organize an appointment inquiry using your pathology, PD-L1 score, molecular report and drug history. Start with the lung cancer resources.

Include prior immune side effects and chest radiation details, if any. We can help clarify the receiving team's record requirements, appointment steps and coordination charges. Drug suitability, supply and treatment timing should be settled with the hospital before travel is built around a particular medicine.

Common questions